Pille Harrison

5.6k total citations · 1 hit paper
53 papers, 2.0k citations indexed

About

Pille Harrison is a scholar working on Genetics, Rheumatology and Genetics. According to data from OpenAlex, Pille Harrison has authored 53 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 18 papers in Rheumatology and 15 papers in Genetics. Recurrent topics in Pille Harrison's work include Chronic Lymphocytic Leukemia Research (19 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Pille Harrison is often cited by papers focused on Chronic Lymphocytic Leukemia Research (19 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Pille Harrison collaborates with scholars based in United Kingdom, Belgium and United States. Pille Harrison's co-authors include Chantal Tasset, Annegret Van der Aa, David M. Reid, Anne Barton, Ann W Morgan, Wendy Thomson, Jane Worthington, Lynne J. Hocking, Sophia Steer and P Wordsworth and has published in prestigious journals such as The Lancet, Nature Genetics and Gastroenterology.

In The Last Decade

Pille Harrison

52 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

2016 344 citations Séverine Vermeire, Stefan Schreiber et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pille Harrison United Kingdom	19	1.0k	662	530	429	413	53	2.0k
Lisy Wang United States	17	1.3k 1.3×	459 0.7×	213 0.4×	421 1.0×	676 1.6×	40	2.0k
G. M. Bartelds Netherlands	13	978 0.9×	1.0k 1.5×	289 0.5×	106 0.2×	334 0.8×	15	1.9k
Bernard Lauwerys Belgium	29	1.4k 1.4×	1.3k 1.9×	131 0.2×	327 0.8×	299 0.7×	84	2.5k
Jörn Drappa United States	21	1.6k 1.6×	2.1k 3.2×	361 0.7×	469 1.1×	237 0.6×	31	3.3k
Marcella Visentini Italy	21	347 0.3×	741 1.1×	242 0.5×	106 0.2×	224 0.5×	67	1.8k
Fabien B. Vincent Australia	19	788 0.8×	1.2k 1.8×	108 0.2×	198 0.5×	157 0.4×	34	1.8k
Michelle Petri United States	17	1.4k 1.4×	1.2k 1.8×	284 0.5×	213 0.5×	228 0.6×	18	2.1k
Kimberly E. Taylor United States	23	763 0.7×	1.1k 1.6×	323 0.6×	271 0.6×	75 0.2×	44	2.0k
Paolo Durigutto Italy	21	658 0.6×	715 1.1×	125 0.2×	139 0.3×	421 1.0×	31	1.6k
Pauline A. van Schouwenburg Netherlands	19	444 0.4×	990 1.5×	246 0.5×	106 0.2×	165 0.4×	32	1.5k

Countries citing papers authored by Pille Harrison

Since Specialization

Citations

This map shows the geographic impact of Pille Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pille Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pille Harrison more than expected).

Fields of papers citing papers by Pille Harrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pille Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pille Harrison. The network helps show where Pille Harrison may publish in the future.

Co-authorship network of co-authors of Pille Harrison

This figure shows the co-authorship network connecting the top 25 collaborators of Pille Harrison. A scholar is included among the top collaborators of Pille Harrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pille Harrison. Pille Harrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Genovese, Mark C., René Westhovens, Luc Meuleners, et al.. (2018). Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Research & Therapy. 20(1). 57–57. 44 indexed citations

Mease, Philip J., Laura C. Coates, Philip Helliwell, et al.. (2018). Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 392(10162). 2367–2377. 156 indexed citations

Kavanaugh, Arthur, Joel M. Kremer, Regina Cseuz, et al.. (2016). Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Annals of the Rheumatic Diseases. 76(6). 1009–1019. 176 indexed citations

Namour, Florence, et al.. (2016). Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions. Drug Metabolism Letters. 10(1). 38–48. 52 indexed citations

Vermeire, Séverine, Stefan Schreiber, Robert Petryka, et al.. (2016). Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. The Lancet. 389(10066). 266–275. 344 indexed citations breakdown →

Jairath, Vipul, David P. Hall, Pille Harrison, et al.. (2012). OC-069 Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic. Gut. 61(Suppl 2). A30.1–A30. 2 indexed citations

Jairath, Vipul, et al.. (2012). PWE-294 Microparticle dependent procoagulant activity and thrombin generation is increased in patients with cirrhosis induced coagulopathy. Gut. 61(Suppl 2). A417.2–A417. 1 indexed citations

Eyre, Stephen, Anne Hinks, John Bowes, et al.. (2010). Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Research & Therapy. 12(5). R175–R175. 78 indexed citations

Barton, Anne, Stephen Eyre, Anne Hinks, et al.. (2010). Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Human Molecular Genetics. 19(22). 4543–4543. 5 indexed citations

10.

Barton, Anne, Stephen Eyre, Xiayi Ke, et al.. (2009). Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Human Molecular Genetics. 18(13). 2518–2522. 61 indexed citations

11.

Orozco, Gisela, Anne Hinks, Stephen Eyre, et al.. (2009). Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Human Molecular Genetics. 18(14). 2693–2699. 75 indexed citations

12.

Hollis‐Moffatt, Jade E., Amanda Phipps‐Green, Marilyn E. Merriman, et al.. (2009). The ITGAVrs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets. Arthritis Research & Therapy. 11(5). R152–R152. 13 indexed citations

13.

Harrison, Pille, J. J. Pointon, K Chapman, Andrew Roddam, & B P Wordsworth. (2008). Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis. Lara D. Veeken. 47(12). 1768–1770. 63 indexed citations

14.

Barton, Anne, Wendy Thomson, Xiayi Ke, et al.. (2008). Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nature Genetics. 40(10). 1156–1159. 108 indexed citations

15.

Harrison, Pille, J. J. Pointon, C. Farrar, Matthew A. Brown, & B. P. Wordsworth. (2006). Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients. Lara D. Veeken. 45(8). 1009–1011. 46 indexed citations

16.

Harrison, Pille, et al.. (2006). MHC2TA promoter polymorphism (-168*G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients. Lara D. Veeken. 46(3). 409–411. 16 indexed citations

17.

Lampropoulos, Christos, Shirish Sangle, Pille Harrison, G. R. V. Hughes, & David D’Cruz. (2004). Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Lara D. Veeken. 43(11). 1383–1385. 56 indexed citations

18.

Harrison, Pille, et al.. (1991). COMPARISON OF FACTOR-VIII CONCENTRATES AND VWFTHP FOR THE TREATMENT OF VONWILLEBRANDS DISEASE. UCL Discovery (University College London). 1 indexed citations

19.

Harrison, Pille & Michael Mullan. (1991). Alzheimer's disease: The significance of a β-amyloid precursor protein gene mutation. 4. 908–913. 1 indexed citations

20.

McKellar, Quintin, et al.. (1990). Pharmacokinetics of fenbendazole in dogs. Journal of Veterinary Pharmacology and Therapeutics. 13(4). 386–392. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact